Is genetic screening necessary for determining the possibility of venous thromboembolism in cancer patients?
Medical Principles and Practice, cilt.21, sa.2, ss.160-163, 2012 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 21 Sayı: 2
- Basım Tarihi: 2012
- Doi Numarası: 10.1159/000333394
- Dergi Adı: Medical Principles and Practice
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.160-163
- Anahtar Kelimeler: Cancer, Mutation, Polymorphism, Venous thromboembolism
- Isparta Uygulamalı Bilimler Üniversitesi Adresli: Hayır
Özet
To determine the risk of an association with some genetic polymorphisms involved in venous thromboembolism (VTE) gene variations (FVL, FV H1299R, FII G20210A, MTHFR C677T, MTHFR A1298C, PAI-1 4G/5G,β-fibrinogen -455 G ] A, FXIII Val34Leu and GpIIIa HPA-1a) in cancer patients. Subjects and Methods: Among 78 cancer patients, 28 who had proven first episode of VTE were selected as the patient group, with 50 control samples selected from age-, sex- and body mass index-matched healthy volunteers (healthy group). The differences in frequency of genetic polymorphisms were found to be statistically insignificant between these two groups. Results: Logistic regression analysis after adjustment for age, sex, smoking and hypertension showed no difference. The screened mutations of these genes were not significantly associated with VTE risk. Conclusion: There is no possible benefit from genetic screening tests regarding VTE in cancer patients. © 2011 S. Karger AG, Basel.